Cargando…

New insights from the application of the FAbry STabilization indEX in a large population of Fabry cases

Mostrar otras versiones (1)

Detalles Bibliográficos
Autores principales:	Mignani, Renzo, Pieroni, Maurizio, Pisani, Antonio, Spada, Marco, Battaglia, Yuri, Verrecchia, Elena, Mangeri, Mario, Feriozzi, Sandro, Tanini, Ilaria, De Danieli, Gianluca, Pieruzzi, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Errata
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577773/ https://www.ncbi.nlm.nih.gov/pubmed/33123367 http://dx.doi.org/10.1093/ckj/sfz010

Ejemplares similares

New insights from the application of the FAbry STabilization indEX in a large population of Fabry cases
por: Mignani, Renzo, et al.
Publicado: (2018)

FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry disease
por: Mignani, Renzo, et al.
Publicado: (2016)

Safety of a protocol for reduction of agalsidase beta infusion time in Fabry disease: An Italian multi-centre study
por: Mignani, Renzo, et al.
Publicado: (2021)

The GALA project: practical recommendations for the use of migalastat in clinical practice on the basis of a structured survey among Italian experts
por: Chimenti, Cristina, et al.
Publicado: (2020)

Fabry nephropathy: a review – how can we optimize the management of Fabry nephropathy?
por: Waldek, Stephen, et al.
Publicado: (2014)

Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease?
por: Duro, Giovanni, et al.
Publicado: (2018)

Will the FAbry STabilization indEX make its way to everyday clinical practice?
por: Cairns, Tereza, et al.
Publicado: (2018)

α-Gal A missense variants associated with Fabry disease can lead to ER stress and induction of the unfolded protein response
por: Consolato, Francesco, et al.
Publicado: (2022)

Deficiency in the Screening Process of Fabry Disease: Analysis of Chronic Kidney Patients Not on Dialysis
por: Battaglia, Yuri, et al.
Publicado: (2021)

Impact of COVID-19 pandemic on patients with Fabry disease: An Italian experience
por: Riccio, Eleonora, et al.
Publicado: (2020)

Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data
por: Riccio, Eleonora, et al.
Publicado: (2020)

Evidence of evolution towards left midventricular obstruction in severe Anderson–Fabry cardiomyopathy
por: Graziani, Francesca, et al.
Publicado: (2020)

Quantitative Analysis of Conjunctival and Retinal Vessels in Fabry Disease
por: Sodi, Andrea, et al.
Publicado: (2019)

Prognostic significance of right ventricular hypertrophy and systolic function in Anderson–Fabry disease
por: Graziani, Francesca, et al.
Publicado: (2020)

Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Isolated microalbuminuria as the first clinical presentation of Fabry disease in an adult heterozygous female
por: Mignani, Renzo, et al.
Publicado: (2009)

Different renal phenotypes in related adult males with Fabry disease with the same classic genotype
por: Mignani, Renzo, et al.
Publicado: (2017)

The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts
por: Germain, Dominique P., et al.
Publicado: (2019)

Motor involvement in Fabry disease
por: Cocozza, Sirio, et al.
Publicado: (2017)

Relapsing minimal change disease superimposed on late-onset p.N215S Fabry nephropathy
por: Salerno, Fabio R, et al.
Publicado: (2021)

Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
por: Hughes, Derralynn, et al.
Publicado: (2021)

Survey about the Quality of Life of Italian Patients with Fabry Disease
por: Polistena, Barbara, et al.
Publicado: (2021)

Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy
por: Morrissey, Ryan P, et al.
Publicado: (2011)

Elevated Ambulatory Blood Pressure Measurements are Associated with a Progressive Form of Fabry Disease
por: Rossi, Federica, et al.
Publicado: (2021)

Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease
por: Cybulla, Markus, et al.
Publicado: (2022)

Erratum to: Relapsing Minimal Change Disease Superimposed on Late-Onset p.N215S Fabry Nephropathy
por: Salerno, Fabio R, et al.
Publicado: (2022)

Potential resistance to SARS-CoV-2 infection in lysosomal storage disorders
por: Pieroni, Maurizio, et al.
Publicado: (2021)

Fabry disease
por: Germain, Dominique P
Publicado: (2010)

Fabry Cardiomyopathy
por: Yoon, Jae Yong, et al.
Publicado: (2013)

DNA methylation impact on Fabry disease
por: Di Risi, Teodolinda, et al.
Publicado: (2021)

Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study
por: Germain, Dominique P., et al.
Publicado: (2018)

Metabolic progression to clinical phenotype in classic Fabry disease
por: Spada, Marco, et al.
Publicado: (2017)

Neuroimaging in Fabry disease: current knowledge and future directions
por: Cocozza, Sirio, et al.
Publicado: (2018)

Skin globotriaosylceramide 3 deposits are specific to Fabry disease with classical mutations and associated with small fibre neuropathy
por: Liguori, Rocco, et al.
Publicado: (2017)

Fabry-Perot interferometers
por: Mora-Hernandez, G
Publicado: (1988)

Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones
por: Cammisa, Marco, et al.
Publicado: (2013)

Migalastat Treatment in a Kidney-Transplanted Patient with Fabry Disease and N215S Mutation: The First Case Report
por: Di Stefano, Valeria, et al.
Publicado: (2021)

Fabry disease and multiple sclerosis misdiagnosis: the role of family history and neurological signs
por: Colomba, Paolo, et al.
Publicado: (2018)

Role of serial cardiac (18)F-FDG PET-MRI in Anderson–Fabry disease: a pilot study
por: Nappi, Carmela, et al.
Publicado: (2021)

Cornea verticillata caused by Fabry diseaseCórnea verticilata por doença de Fabry
por: Costa, Ana Luiza Fontes de Azevedo, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jg661qprljlj9ser21aa8k4ft6